A457
| Code | Size | Price |
|---|
| TAR-T23595-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T23595-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T23595-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
A457 is an antagonist of the prokineticin receptor.
CAS:
1233923-95-9
Formula:
C26H33ClN2O3
Molecular Weight:
457.01
Purity:
0.98
SMILES:
CC(C)CN(Cc1cc(Cl)c2OCCCOc2c1)C(=O)C1CCN(Cc2ccccc2)C1
References
1. Deihim B, Hassanzadeh M, Shafiei-Jandaghi NZ, Amanlou M, Douraghi M. Characterization of the DNA mismatch repair proteins MutS and MutL in a hypermutator Acinetobacter baumannii. Microb Pathog. 2017 Dec;113:74-84. doi: 10.1016/j.micpath.2017.10.001. Epub 2017 Oct 5. PubMed PMID: 28988868.
2. Li M, Wu H, Yang Q, Ke H, Yin B, Shi Q, Wang W, Wei Q, Xie G, Chen S. Experimental and Theoretical Interpretation on the Magnetic Behavior in a Series of Pentagonal-Bipyramidal Dy(III) Single-Ion Magnets. Chemistry. 2017 Dec 14;23(70):17775-17787. doi: 10.1002/chem.201703755. Epub 2017 Nov 8. PubMed PMID: 28984390.
3. Graham C, Knox H, Hess LM, Jen M, Cuyun Carter G, Chandrawansa K, Boye M. Cost-Effectiveness In The Second-Line Treatment Of Non-Small Cell Lung Cancer (Nsclc) In The Us. Value Health. 2015 Nov;18(7):A457-8. doi: 10.1016/j.jval.2015.09.1174. Epub 2015 Oct 20. PubMed PMID: 26532571.
4. Dorey J, Disset A, Elmoctar Neine M, Plun-Favreau J, Toumi M. A Cost-Effectiveness Analysis Of A Genomic Test Compared To Standard Of Care In Breast Cancer Patients In France. Value Health. 2015 Nov;18(7):A457. doi: 10.1016/j.jval.2015.09.1172. Epub 2015 Oct 20. PubMed PMID: 26532570.